Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Regeneron Pharmaceuticals : shares poised for rebound - Barron's

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2017 | 07:04pm CET

Shares of Regeneron Pharmaceuticals Inc, which tumbled 32 percent in 2016, are poised for a rebound, the financial newspaper Barron's said.

A better-than-expected launch of Regeneron's skin treatment Dupixent caused shares to soar last week, the paper reported in its May 8 edition. If Dupixent usage grows faster than expected, it could take pressure off Regeneron's other drugs, including eye drug Eylea, Barron's said.

Regeneron said that 900 prescriptions had been written for Dupixent and that the number of doctors prescribing the drug had jumped by nearly 50 percent.

(Reporting by Olivia Oran; Editing by Phil Berlowitz)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
01/19 REGENERON PHARMACEUTICALS : and Sanofi To Accelerate and Expand Investment for C..
01/18 REGENERON PHARMACEUTICALS INC : Change in Directors or Principal Officers (form ..
01/11 REGENERON PHARMACEUTICALS : forms consortium to accelerate largest widely-availa..
01/09 SANOFI : and Regeneron to accelerate and expand investment for cemiplimab and du..
01/08 SANOFI : and Regeneron boost investment in cancer drug cemiplimab
01/08 REGENERON PHARMACEUTICALS : and Sanofi To Accelerate and Expand Investment for C..
01/08 REGENERON PHARMACEUTICALS : Forms Consortium of Leading Life Sciences Companies ..
01/04 REGENERON PHARMACEUTICALS : Researchers Submit Patent Application, "Animal Model..
01/02 REGENERON PHARMACEUTICALS INC : Change in Directors or Principal Officers (form ..
2017 REGENERON PHARMACEUTICALS : Announces Presentation at the 36th Annual J.P. Morga..
More news
News from SeekingAlpha
01/19 The Passive/Aggressive Portfolio
01/19 A LITTLE MORE RISK BEAT THE MARKET : Week 7
01/17 De-Risking Catalysts Aplenty - Cara Therapeutics
01/17 POLEN CAPITAL : Portfolio Manager Commentary Q4 2017
01/16 Alder Biopharmaceuticals - Modeling The Risk/Reward
Financials ($)
Sales 2017 5 768 M
EBIT 2017 2 453 M
Net income 2017 1 481 M
Finance 2017 2 252 M
Yield 2017 -
P/E ratio 2017 29,15
P/E ratio 2018 26,72
EV / Sales 2017 6,53x
EV / Sales 2018 5,75x
Capitalization 39 917 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 447 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Charles A. Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-0.50%39 917
GILEAD SCIENCES14.10%105 754
VERTEX PHARMACEUTICALS4.76%39 951
GENMAB10.50%11 762
EXELIXIS, INC.-9.57%8 284
BLUEBIRD BIO INC2.25%8 064